Robert Blazej, PhD Principal
For the past four years, Robert directed Novozymes’ Digital Biotechnology unit in San Francisco and their global biotechnology scouting team. Previously,
Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that mircrodoplets would transform the scale and pace of life
science research. Allopartis was acquired by Novozymes in 2013.
Robert earned his Ph.D. in 2006 in Bioengineering jointly from UC Berkeley and UC San Francisco. His graduate research focused on the design, implementation
and characterization of microfluidic systems for next-generation DNA sequencing. Blazej is a published contributor to the human, drosophila, and
canine genome projects, with his work on integrated microfluidic DNA sequencing featured on the cover of PNAS and in Nature.